Shehnaaz Suliman, M.D., M.Phil., M.B.A.

Shehnaaz joined the Parvus Board in 2017 and serves as an independent strategic advisor to life sciences companies. Most recently she was SVP, Corporate Development and Strategy at Therevance where she was responsible for leading the company’s business development activities and corporate strategy. Prior to joining Theravance Biopharma, Dr. Suliman was Vice President and Global Therapeutic Head, Roche Partnering based at Genentech since May 2015 where she led a global team focused on strategic licensing and acquisition transactions. Since September 2010, Dr. Suliman was a Group Leader and Project Team Leader in the Genentech R&D Portfolio Management and Operations Group with oversight for early and clinical drug development programs in immunology, infectious diseases, neurosciences, cardiovascular, metabolism and ophthalmology. Prior to that, Dr. Suliman held various management roles at Gilead Sciences over a period of six years since January 2005, where she played a leading role in defining and executing Gilead’s licensing, mergers and acquisitions strategy into new therapeutic areas. Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners prior to Gilead, advising public and private companies on buy- and sell-side transactions from 2002-2004. Dr. Suliman received her M.D. at the University of Cape Town Medical School, South Africa, and holds an M.B.A, with distinction, and Masters in Development Studies degrees from Oxford University, where she was a Rhodes Scholar.